BMJ:他汀类药物治疗与肌肉不良事件

2021-03-02 MedSci原创 MedSci原创

先前因他汀类药物治疗导致肌肉不良事件的参与者,继续接受阿托伐他汀不会对其肌肉症状产生影响,多数参与者在完成研究后考虑重新开始他汀类药物治疗

他汀类药物可有效预防风险人群的血管疾病事件,但部分患者会出现严重的副作用,如肌病(每10000人治疗年中约有1人),甚至会发展为严重的横纹肌溶解(每10万人治疗年中约有0.2人)。相比于严重的肌肉症状,汀类药物治疗引起的肌肉疼痛较为常见。
近日研究人员开展n-of-1试验,考察了对于先前服用他汀类药物曾报告过肌肉不良症状的人群,继续服用他汀类药物对肌肉症状的影响。
本次研究为随机、安慰剂对照研究,于2016年12月至2018年4月在英国50个初级保健机构开展,200名最近因为肌肉不良症状停止或正在考虑停止他汀类药物治疗的患者参与,参与者随机接受6个疗程的干预,每天服用20mg阿托伐他汀或安慰剂,每个疗程持续2个月。研究的主要终点为各个疗程视觉模拟评分法(VAS,0-10)评估的肌肉症状。
 
151名参与者提供了他汀类药物治疗期和安慰剂治疗期的VAS症状评分。总体而言,他汀类药物治疗期间与安慰剂治疗期间的肌肉症状得分无显著差异(他汀类药物与安慰剂的平均差异-0.11)。在他汀类药物治疗期间,有18名参与者(9%)因无法忍受的肌肉症状而停药,而在安慰剂治疗期间,有13名参与者(7%)因无法忍受的肌肉症状而停药。在完成试验的参与者中,三分之二重新开始长期他汀类药物治疗。
研究认为,先前因他汀类药物治疗导致肌肉不良事件的参与者,继续接受阿托伐他汀不会对其肌肉症状产生影响,多数参与者在完成研究后考虑重新开始他汀类药物治疗
 
原始出处:
 

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1849198, encodeId=ee1c18491988b, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Thu Oct 14 03:34:21 CST 2021, time=2021-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044603, encodeId=b987204460367, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Thu Apr 08 11:34:21 CST 2021, time=2021-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=945112, encodeId=9bd7945112b1, content=重新始他汀类治疗的剂量有无变化?, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210703/9c448fe1b3b54fd7bc9477662f4861bb/4bdadad22bfd46f2921aabb4c40265d3.jpg, createdBy=a8d81938466, createdName=weigq, createdTime=Wed Mar 03 13:51:52 CST 2021, time=2021-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=945059, encodeId=0a5a94505967, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db732100259, createdName=1311f65ab2m, createdTime=Wed Mar 03 10:00:54 CST 2021, time=2021-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944904, encodeId=d88c944904e0, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Mar 02 19:45:15 CST 2021, time=2021-03-02, status=1, ipAttribution=)]
    2021-10-14 gaoxiaoe
  2. [GetPortalCommentsPageByObjectIdResponse(id=1849198, encodeId=ee1c18491988b, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Thu Oct 14 03:34:21 CST 2021, time=2021-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044603, encodeId=b987204460367, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Thu Apr 08 11:34:21 CST 2021, time=2021-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=945112, encodeId=9bd7945112b1, content=重新始他汀类治疗的剂量有无变化?, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210703/9c448fe1b3b54fd7bc9477662f4861bb/4bdadad22bfd46f2921aabb4c40265d3.jpg, createdBy=a8d81938466, createdName=weigq, createdTime=Wed Mar 03 13:51:52 CST 2021, time=2021-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=945059, encodeId=0a5a94505967, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db732100259, createdName=1311f65ab2m, createdTime=Wed Mar 03 10:00:54 CST 2021, time=2021-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944904, encodeId=d88c944904e0, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Mar 02 19:45:15 CST 2021, time=2021-03-02, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1849198, encodeId=ee1c18491988b, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Thu Oct 14 03:34:21 CST 2021, time=2021-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044603, encodeId=b987204460367, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Thu Apr 08 11:34:21 CST 2021, time=2021-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=945112, encodeId=9bd7945112b1, content=重新始他汀类治疗的剂量有无变化?, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210703/9c448fe1b3b54fd7bc9477662f4861bb/4bdadad22bfd46f2921aabb4c40265d3.jpg, createdBy=a8d81938466, createdName=weigq, createdTime=Wed Mar 03 13:51:52 CST 2021, time=2021-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=945059, encodeId=0a5a94505967, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db732100259, createdName=1311f65ab2m, createdTime=Wed Mar 03 10:00:54 CST 2021, time=2021-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944904, encodeId=d88c944904e0, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Mar 02 19:45:15 CST 2021, time=2021-03-02, status=1, ipAttribution=)]
    2021-03-03 weigq

    重新始他汀类治疗的剂量有无变化?

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1849198, encodeId=ee1c18491988b, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Thu Oct 14 03:34:21 CST 2021, time=2021-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044603, encodeId=b987204460367, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Thu Apr 08 11:34:21 CST 2021, time=2021-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=945112, encodeId=9bd7945112b1, content=重新始他汀类治疗的剂量有无变化?, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210703/9c448fe1b3b54fd7bc9477662f4861bb/4bdadad22bfd46f2921aabb4c40265d3.jpg, createdBy=a8d81938466, createdName=weigq, createdTime=Wed Mar 03 13:51:52 CST 2021, time=2021-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=945059, encodeId=0a5a94505967, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db732100259, createdName=1311f65ab2m, createdTime=Wed Mar 03 10:00:54 CST 2021, time=2021-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944904, encodeId=d88c944904e0, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Mar 02 19:45:15 CST 2021, time=2021-03-02, status=1, ipAttribution=)]
    2021-03-03 1311f65ab2m

    谢谢分享

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1849198, encodeId=ee1c18491988b, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Thu Oct 14 03:34:21 CST 2021, time=2021-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044603, encodeId=b987204460367, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Thu Apr 08 11:34:21 CST 2021, time=2021-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=945112, encodeId=9bd7945112b1, content=重新始他汀类治疗的剂量有无变化?, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210703/9c448fe1b3b54fd7bc9477662f4861bb/4bdadad22bfd46f2921aabb4c40265d3.jpg, createdBy=a8d81938466, createdName=weigq, createdTime=Wed Mar 03 13:51:52 CST 2021, time=2021-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=945059, encodeId=0a5a94505967, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db732100259, createdName=1311f65ab2m, createdTime=Wed Mar 03 10:00:54 CST 2021, time=2021-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944904, encodeId=d88c944904e0, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Mar 02 19:45:15 CST 2021, time=2021-03-02, status=1, ipAttribution=)]
    2021-03-02 1209e435m98(暂无昵称)

    学习了,谢谢分享

    0

相关资讯

Eur Heart J:心肌梗死患者LDL-C降低和他汀类药物治疗强度与主要不良结局

MI后早期LDL-C降低程度较大和高强度他汀类药物治疗,与降低所有CV结局和全因死亡率的风险有关。这些结果支持了临床试验数据,提示在MI后早期降低LDL-C具有最大益处。

Stroke:缺血性卒中老年人服用他汀类药物治疗的很大年龄

尽管缺乏预防复发性心血管疾病的证据,但他汀类药物经常在80岁及以上缺血性卒中患者中才开始使用。近日,心血管疾病领域权威杂志Stroke上发表了一篇研究文章,在这项研究中,研究人员旨在寻找年龄最大的他汀

JAHA:大血管闭塞性急性缺血性卒中发作后他汀类药物的疗效

急性LVO发作后给予他汀类药物治疗与90天内更好的功能预后和死亡率显著相关。

ATVB:他汀类药物对COVID-19相关结局的益处

尽管他汀类药物被广泛作为降脂药用于处方,但由于他汀类药物会增加ACE2的表达,因此在新冠肺炎COVID-19流行情况下它们使用的安全性令人担忧。近日,心血管领域权威杂志Arteriosclerosis

JAMA Netw Open:术中使用他汀类药物可明显降低腹部手术术后粘连相关并发症发生率

粘连相关并发症(ARC),包括小肠梗阻,是腹部手术的常见并发症。他汀类药物具有抗纤维化的多重作用,在小鼠模型中可抑制粘连形成,但尚未在人类中进行过评估。

Otolaryngol Head Neck Surg:突发感音神经性听力损失与他汀类药物使用史之间的关系

他汀类药物对突发感音神经性听力损失(SSNHL)的影响仍不清楚。最近,有研究人员调查了先前使用他汀与SSNHL之间的相关性。